• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Eloxx Pharmaceuticals Inc.

    1/24/24 5:11:27 PM ET
    $ELOX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ELOX alert in real time by email
    S-8 1 tm243993d1_s8.htm S-8

    As filed with the Securities and Exchange Commission on January 24, 2024

     

    Registration No. 333-            

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

     

    Eloxx Pharmaceuticals, Inc.

    (Exact name of registrant as specified in its charter)

      

     

    Delaware 84-1368850

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

     

    480 Arsenal Way

    Watertown, Massachusetts 02472

    (781) 577-5300

    (Address, including zip code and telephone number, including area code, of Registrant’s principal executive offices)

     

    ELOXX PHARMACEUTICALS, INC. 2018 EQUITY INCENTIVE PLAN

    (Full title of the plan)

     

    Sumit Aggarwal

    Chief Executive Officer

    Eloxx Pharmaceuticals, Inc.

    480 Arsenal Way

    Watertown, Massachusetts 02472

    (Name and address of agent for service)

     

    (914) 207-2300

    (Telephone number, including area code, of agent for service)

     

    Copies to:

     

    Peter N. Handrinos, Esq.

    Wesley C. Holmes, Esq.

    Ellen Smiley, Esq.

    Latham & Watkins LLP

    200 Clarendon Street, 27th Floor

    Boston, MA 02116

    (617) 948-6000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer  ¨ Accelerated filer  ¨
    Non-accelerated filer  x Smaller reporting company  x
        Emerging growth company  ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

      

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 is being filed with the Securities and Exchange Commission (the “Commission”) for the purpose of registering an additional 157,170 shares (the “Additional Shares”) of common stock, par value $0.01 per share (the “Common Stock”), of Eloxx Pharmaceuticals, Inc. (the “Registrant”) issuable under the Registrant’s 2018 Equity Incentive Plan (the “2018 Plan”) pursuant to the provision of the 2018 Plan which provides for an annual automatic increase in the number of shares of Common Stock reserved for issuance under the 2018 Plan.

     

    The Additional Shares are securities of the same class as other securities for which prior registration statements of the Registrant on Form S-8 were previously filed with the Commission on March 31, 2023 (File No. 333-271035), March 12, 2021 (File No. 333-254201), March 6, 2020 (File No. 333-236952), May 11, 2018 (File No. 333-224860) and January 10, 2018 (File No. 333-222499).

     

    Pursuant to General Instruction E of Form S-8, the contents of the above-referenced prior registration statements are incorporated into this Registration Statement by reference to the extent not modified or superseded hereby or by any subsequently filed document, which is incorporated by reference herein or therein.

     

    Item 8. Exhibits.

     

    Exhibit
    Number
      Exhibit Description   Form   File No.   Exhibit
    Number
      Filing Date Filed
    Herewith
    4.1   Amended and Restated Certificate of Incorporation of Senesco Technologies, Inc. filed with the State of Delaware on January 22, 2007   10-Q   001-31326   3.1   2/14/2007  
                           
    4.2   Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Senesco Technologies, Inc. filed with the State of Delaware on December 13, 2007   10-Q   001-31326   3.1   2/14/2008  
                           
    4.3   Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Senesco Technologies, Inc. filed with the State of Delaware on September 22, 2009   10-K   001-31326   3.3   9/28/2009  

     

     

     

     

    Exhibit
    Number
      Exhibit Description   Form   File No.   Exhibit
    Number
      Filing Date Filed
    Herewith
    4.4   Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Senesco Technologies, Inc. filed with the State of Delaware on May 25, 2010   8-K   001-31326   3.1   5/28/2010  
                           
    4.5   Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Senesco Technologies, Inc. filed with the State of Delaware on December 22, 2011   10-Q   001-31326   3.1   2/14/2012  
                           
    4.6   Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Senesco Technologies, Inc. filed with the State of Delaware on April 1, 2013   10-Q   001-31326   3.1   5/15/2013  
                           
    4.7   Certificate of Amendment to the Registrant’s Amended and Restated Certificate of Incorporation, as filed with the Secretary of State of the State of Delaware on October 16, 2013   8-K   001-31326   3.1   10/21/2013  
                           
    4.8   Certificate of Amendment to the Registrant’s Amended and Restated Certificate of Incorporation, as filed with the Secretary of State of the State of Delaware on September 29, 2014   8-K   001-31326   3.1   10/3/2014  
                           
    4.9   Certificate of Amendment to the Registrant’s Amended and Restated Certificate of Incorporation, as filed with the Secretary of State of the State of Delaware on December 19, 2017   8-K   001-31326   3.1   12/22/2017  
                           
    4.10   Certificate of Amendment to the Registrant’s Amended and Restated Certificate of Incorporation, as filed with the Secretary of State of the State of Delaware on December 19, 2017   8-K   001-31326   3.2   12/22/2017  
                           
    4.11   Certificate of Amendment to Amended and Restated Certificate of Incorporation of Eloxx Pharmaceuticals, Inc., as filed with the Secretary of State of the State of Delaware on December 1, 2022   8-K   001-31326   3.1   12/1/2022  
                           
    4.12   Amended and Restated Bylaws   8-K   001-31326   3.2   12/27/17  

     

     

     

     

    Exhibit
    Number
      Exhibit Description   Form   File No.   Exhibit
    Number
      Filing Date Filed
    Herewith
    4.1   Specimen of Common Stock Certificate   10-K   001-31326   4.1   3/16/2018  
                           
    5.1   Opinion of Latham & Watkins LLP                 *
                           
    23.1   Consent of Baker Tilly US, LLP                 *
                           
    23.2   Consent of Latham & Watkins LLP (included in Exhibit 5.1).                 *
                           
    24.1   Power of Attorney (included on signature page)                 *
                           
    99.1   Eloxx Pharmaceuticals, Inc. 2018 Equity Incentive Plan   8-K   001-31326   10.1   3/30/2018  
                           
    99.2   Form of Stock Option Grant Notice, Option Agreement and Notice of Exercise under the Eloxx Pharmaceuticals, Inc. 2018 Equity Incentive Plan   8-K   001-31326   10.2   3/30/2018  
                           
    99.3   Israeli Sub-Plan under the Eloxx Pharmaceuticals, Inc. 2018 Equity Incentive Plan   8-K   001-31326   10.3   3/30/2018  
                           
    99.4   Form of Israeli Stock Option Grant Package under the Israeli Sub-Plan under the Eloxx Pharmaceuticals, Inc. 2018 Equity Incentive Plan   8-K   001-31326   10.4   3/30/2018  
                           
    99.5   Form of Restricted Stock Unit Grant Notice for non-Israeli employees   S-8   333-224860   99.5   5/11/2108  
                           
    99.6   Form of Restricted Stock Unit Grant Notice for Israeli employees   10-Q   001-31326   10.6   8/10/2018  
                           
    107.1   Filing Fee Table                 *

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Watertown, State of Massachusetts, on this 24th day of January 2024.

     

     

    ELOXX PHARMACEUTICALS, INC.

                                       
     

    By

    /s/ Sumit Aggarwal

      Name

    Sumit Aggarwal

      Title

    Chief Executive Officer

     

    POWER OF ATTORNEY

     

    We, the undersigned officers and directors of Eloxx Pharmaceuticals, Inc., hereby severally constitute and appoint Sumit Aggarwal and Daniel Geffken, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to sign any registration statement for the same offering covered by this registration statement that is to be effective upon filing pursuant to Rule 462(b) promulgated under the Securities Act, and all post-effective amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities held on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Sumit Aggarwal   Chief Executive Officer and Director
    (Principal Executive Officer)
        January 24, 2024
    Sumit Aggarwal      
         
    /s/ Daniel Geffken   Interim Chief Financial Officer
    (Principal Financial and Accounting Officer)
      January 24, 2024
    Daniel Geffken      
         
    /s/ Steven D. Rubin   Director   January 24, 2024
    Steven D. Rubin      
           
    /s/ Lindsay Androski   Director   January 24, 2024
    Lindsay Androski      
           
    /s/ Alan Walts, Ph.D.   Director   January 24, 2024
    Alan Walts, Ph.D.        

     

     

     

    Get the next $ELOX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ELOX

    DatePrice TargetRatingAnalyst
    12/17/2021$4.00Outperform
    Oppenheimer
    11/18/2021$2.00 → $1.00Neutral
    HC Wainwright & Co.
    11/11/2021$3.00 → $2.00Neutral
    HC Wainwright & Co.
    6/30/2021$3.10Buy
    Mizuho
    More analyst ratings

    $ELOX
    SEC Filings

    See more
    • SEC Form NT 10-Q filed by Eloxx Pharmaceuticals Inc.

      NT 10-Q - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)

      11/19/24 4:01:28 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eloxx Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)

      10/17/24 4:01:29 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form NT 10-Q filed by Eloxx Pharmaceuticals Inc.

      NT 10-Q - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)

      8/14/24 4:01:27 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELOX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Eloxx Pharmaceuticals with a new price target

      Oppenheimer initiated coverage of Eloxx Pharmaceuticals with a rating of Outperform and set a new price target of $4.00

      12/17/21 5:45:41 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on Eloxx Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Eloxx Pharmaceuticals with a rating of Neutral and set a new price target of $1.00 from $2.00 previously

      11/18/21 6:16:16 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on Eloxx Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Eloxx Pharmaceuticals with a rating of Neutral and set a new price target of $2.00 from $3.00 previously

      11/11/21 6:39:05 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELOX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Walts Alan Edmund was granted 12,000 shares, increasing direct ownership by 1,274% to 12,942 units (SEC Form 4)

      4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)

      10/17/24 4:02:21 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Androski Lindsay was granted 12,000 shares (SEC Form 4)

      4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)

      10/17/24 4:01:56 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Rubin Steven D was granted 12,000 shares (SEC Form 4)

      4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)

      10/17/24 4:01:36 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELOX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Eloxx Pharmaceuticals Announces Key Corporate Accomplishments

      Data from Eloxx's proof-of-concept trial in patients with nonsense mutation Alport Syndrome (NMAS) presented in late-breaking presentation at American Society of Nephrology (ASN) Kidney Week New protein analyses confirm production of both collagen alpha 4 and collagen alpha 5 in patients post treatment with ELX-02 Results justify the need to conduct a larger clinical trial of ELX-02 in NMAS to confirm clinical benefit U.S. Food and Drug Administration (FDA) allows for continued dosing of subjects in Phase 1 trial of ZKN-013 WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (OTC:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases w

      11/12/24 4:05:00 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eloxx Pharmaceuticals Provides Pipeline and Financing Updates

      First two subjects dosed in Phase 1 clinical trial of ZKN-013; ZKN-013 is being developed for the potential treatment of rare dermatological and other diseases associated with nonsense mutations Positive written FDA feedback and guidance from a pre-Investigational New Drug Application (PIND) meeting provides pathway to IND application submission to initiate a Phase 2 clinical trial in the US with ELX-02 in patients with nonsense mutation alport syndrome (NMAS) Secured binding commitment for additional $3.2 million financing to advance our clinical programs WATERTOWN, Mass., July 11, 2024 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (OTC:ELOX), a leader in ribosomal RNA-targeted gene

      7/11/24 11:46:35 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates

      ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome Pre-Investigational New Drug (IND) Meeting Requested with U.S. FDA for ELX-02 to Discuss Planned next Study In Nonsense Mutation Alport Syndrome Signed Global Licensing Partnership for ZKN-013 with Almirall Pharmaceuticals with $3M upfront and up to $470M in milestones and Tiered Royalties on Global Sales New Paper Published on Autosomal Dominant Polycystic Kidney Disease (ADPKD) shows that ELX-02 treatment prevents cyst formation in diseased PKD organoids with nonsense mutations and a single healthy gene copy WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWI

      4/16/24 7:30:00 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELOX
    Leadership Updates

    Live Leadership Updates

    See more
    • Cognito Therapeutics Appoints Greg Weaver as Chief Financial Officer

      Cognito Therapeutics, a pioneer developing disease-modifying therapeutics to treat CNS diseases, today announced the appointment of Greg Weaver as Chief Financial Officer (CFO), to lead all finance-related and investor relations functions at the Company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017630946/en/Greg Weaver, CFO, Cognito Therapeutics (Photo: Business Wire) Mr. Weaver is a highly accomplished finance executive who brings more than 30 years of life sciences, financial and operations experience to Cognito. Most recently, he served as CFO of Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage oncology comp

      10/17/23 8:00:00 AM ET
      $ATAI
      $ATOS
      $ELOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer

      SEATTLE, June 01, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a current focus on breast cancer, today announces the appointment of Greg Weaver as the Company's new Chief Financial Officer (CFO). Mr. Weaver succeeds Kyle Guse. A short video interview with Mr. Weaver about his background and vision for Atossa can be found here: https://youtu.be/G6ZzHLh-qsQ Mr. Weaver brings more than 30 years of life sciences, financial and operations experience to the Company. Recently, he served as CFO of privately held BioIntelliSense, a commerc

      6/1/23 9:10:00 AM ET
      $ATAI
      $ATOS
      $ELOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Eloxx Pharmaceuticals Announces Changes to Board of Directors

      Lindsay Androski, JD, MBA brings significant experience growing biotech companies through her roles as an executive at Roivant Social Ventures Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr. Jasbir Seehra step down from the Eloxx board WATERTOWN, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the appointment of Lindsay Androski, JD, MBA to its board of directors and as a member of the Board's Audit Committee and Compensation Committee. Current board members Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr.

      7/5/22 8:00:00 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELOX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Eloxx Pharmaceuticals Inc.

      SC 13D/A - Eloxx Pharmaceuticals, Inc. (0001035354) (Subject)

      8/20/24 8:13:16 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Eloxx Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Eloxx Pharmaceuticals, Inc. (0001035354) (Subject)

      2/13/23 4:52:16 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Eloxx Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Eloxx Pharmaceuticals, Inc. (0001035354) (Subject)

      2/14/22 6:18:22 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELOX
    Financials

    Live finance-specific insights

    See more
    • Eloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients

      Combination of subcutaneous ELX-02 with ivacaftor did not achieve statistical significance for efficacy endpoints in Phase 2 study in Class 1 CF ELX-02 was well tolerated with no drug-related serious adverse events observed Evidence of activity for ELX-02 observed; efficacy signal potentially confounded by variability due to low drug exposure Path forward for ELX-02 for the treatment of Class 1 CF to be determined together with CF Foundation Company to host conference call and webcast today, September 14, 2022, at 4:30 p.m. ET WATERTOWN, Mass., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare d

      9/14/22 4:05:00 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2 Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients

      ELX-02 monotherapy dosed at 1.5mg/kg/day demonstrated a statistically significant 5.4mmol/L mean sweat chloride reduction, an established surrogate for restoration of CFTR biological activity ELX-02 monotherapy results support advancement of ELX-02 into Phase 3 clinical development First patient dosed in Phase 2 ELX-02 expansion treatment arms evaluating combination with ivacaftor; topline data expected by the end of the first half of 2022 Company to host conference call and webcast Wednesday, November 17, 2021 at 8:30 am ET WATERTOWN, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare dise

      11/17/21 7:00:00 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eloxx Pharmaceuticals Acquires Zikani Therapeutics

      Combined Company to be Leader in Ribosomal RNA-Targeted Genetic Therapy Bringing Together Complementary Platforms Maximizes Potential for ELX-02 for Cystic Fibrosis in Phase 2 Development Adds Preclinical Stage Pipeline in Rare Diseases and Oncology Targeting RNA and Ribosomal Mutations Expects to File IND for First Oral Drug to Treat Patients with Recessive Dystrophic and Junctional Epidermolysis Bullosa (RDEB and JEB) Sumit Aggarwal, Zikani President and CEO, to Lead the Combined Company Eloxx to Issue Approximately 7.6 Million Shares to Zikani Stockholders Company to Host Investor Call at 8:30 a.m. ET, April 1 WALTHAM, Mass. and WATERTOWN, Mass., April 01, 2021 (GLOBE NEWSWIRE

      4/1/21 7:45:00 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care